Goodwin Biotechnology signs BioThrax process development sub-contract with Emergent

Under the contract, early stage proof-of-concept feasibility process development will be conducted to identify concentrating AVA filtrate for storage before the downstream process for vaccine.

GBI process development vice president Muctarr Sesay said, "Our goal is to develop process parameters that are amenable to routine GMP production and large-scale manufacturing in an effort to contribute to the production of BioThrax at large scale."

Emergent BioSolutions, Biodefense Division process development engineer Heidi Nielsen said, "We chose to work with Goodwin Biotechnology based on their Quality Systems and experience with large scale, GMP-compliant protein purification and processing."

Anthrax, caused by the bacteria Bacillus anthracis, spreads by endospores that can survive in harsh conditions for long periods of time.